International Journal of Radiation Oncology, Biology, Physics 17(1): 21-27, 1989.
Ingram SS, Rosenman J, Heath R, et al.
Recent reports have suggested that the presence of progesterone receptor correlates with other well-known predictors of a favorable outcome for endometrial cancer patients. To test this hypothesis, we reviewed the records of 154 patients who had undergone a hysterectomy for adenocarcinoma of the endometrium, and pelvic irradiation if poor prognostic factors were present. The 3-year disease-free survival for all clinical Stage I patients was 80%. Patients with progesterone receptor levels greater than or equal to 100 had a 3-year disease-free survival of 93% compared with only a 36% 3-year disease-free survival for patients with progesterone receptor less than 100 (p less than .0001, log rank test). To determine whether elevated progesterone receptor was an independent prognostic factor for disease-free survival in endometrial cancer, or just correlated with the other well-known predictors, bivariate and multivariate analyses were conducted. Our results indicate that progesterone receptor levels are the single most important prognostic indicator of 3-year disease-free survival in clinical Stage I endometrial cancer, with only cervical involvement and peritoneal cytology being significant prognostic variables after adjusting for progesterone receptor levels.
Rheinische Friedrich- Wilhelms- Universität Bonn